NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege GmbH

Ulm 19 trials 7 recruiting

19 Registered trials

7 Currently recruiting

Organisation

NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege GmbH

Location

Ulm, Germany

Identifier

ORG-100044711

Address

Muensterplatz 32, Mitte, 89073, Germany

Departments

-
#2206: NeuroPoint
#276007; Neurology
#3202, Neuropoint Studienzentrum
1107
6704: Neuropoint GmbH
7125
N/A
Nervenarztliche Gemeinschaftspraxis
Neurology
Studienzentrum
Studienzentrum Neuropoint GmbH
Ν/Α

Clinical trials at this site (19)

Search interface

A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman… Not authorised

2023-507633-21-00 Neurological Disease 5
A Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Treatment in Patie… Recruiting

2023-507633-21-01 Multiple Sclerosis 5 2024-12-09
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 multiple sclerosis 5 2024-10-17
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Recruiting

2024-511101-28-00 Episodic Migraine Chronic Migraine 4 2026-02-24
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
Silexan® in mild to moderate major depressive disorder Recruiting

2025-521744-37-00 Mild to moderate major depressive disorder 5 2025-11-17
Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o… Recruiting

2023-509275-17-00 Relapsing multiple sclerosis 5 2025-10-06
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended

2023-506429-13-00 Progressive multiple sclerosis (PMS) 5 2018-05-02
“A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended

2023-503289-22-00 Relapsing Multiple Sclerosis 4 2024-07-05
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 relapsing multiple sclerosis (RMS) 5 2021-07-23